In fact, anti-CD20 therapy on MS patients has shown promising results in reducing the pro-inflammatory responses of autoreactive CD4+ and CD8+ T lymphocytes, limiting disease remission [36]. The gene discussed is CD8A; the disease is myeloid sarcoma.